BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2024 8:28:55 AM | Browse: 512 | Download: 996
Publication Name World Journal of Clinical Oncology
Manuscript ID 95981
Country China
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy
Manuscript Source Invited Manuscript
All Author List Dong-Ling Wan and Li-Qi Sun
ORCID
Author(s) ORCID Number
Dong-Ling Wan http://orcid.org/0009-0005-9124-6333
Li-Qi Sun http://orcid.org/0000-0002-1151-3931
Funding Agency and Grant Number
Corresponding Author Li-Qi Sun, MD, Doctor, Doctor, Department of Gastroenterology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China. zjhzslqsmmu@foxmail.com
Key Words Hepatocellular carcinoma; Hepatitis B virus; Hepatectomy; Antiviral therapy; Hepatitis B virus-DNA; Hepatitis B virus-DNA
Core Tip Hepatocellular carcinoma (HCC) is one of the most common and highly fatal malignancies worldwide and is usually associated with hepatitis B virus (HBV) infection. Hepatectomy is a widely accepted curative treatment for HCC, but the long-term survival rate is still unsatisfactory due to the high recurrence rate after resection. Preoperative or postoperative antiviral therapy plays an important role in improving the prognosis for HBV-related HCC patients who underwent hepatectomy. Therefore, we explored when antiviral therapy is more appropriate and whether perioperative rescue antiviral therapy can achieve the effect of preoperative long-term antiviral therapy in the paper.
Publish Date 2024-08-29 08:28
Citation

Wan DL, Sun LQ. Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy. World J Clin Oncol 2024; 15(9): 1251-1255

URL https://www.wjgnet.com/2218-4333/full/v15/i9/1251.htm
DOI https://dx.doi.org/10.5306/wjco.v15.i9.1251
Full Article (PDF) WJCO-15-1251-with-cover.pdf